Wearable Robotics closes €5M Series A and accelerates expansion
- Marc Griffith
- 1 day ago
- 4 min read
Summary Wearable Robotics, a spin-off of Scuola Superiore Sant'Anna, closed a €5 million Series A round led by CDP Venture Capital to expand product portfolio, strengthen regulatory compliance, and boost commercial channels toward key markets, with a particular focus on North America. Key takeaways
|
Wearable robotics for rehabilitation is at the heart of Wearable Robotics' growth strategy, which has just closed a €5 million Series A to accelerate global expansion and bring its solutions to strategic markets. The capital raised will be used to expand the product portfolio, complete regulatory pathways, and strengthen business development.
Why wearable robotics for rehabilitation matters today
Neuromotor rehabilitation is changing thanks to devices that combine mechatronics, adaptive control, and user interfaces based on augmented reality: solutions that enable more intensive and personalized therapeutic pathways. Offering modular and integrable systems increases adherence to therapy and opens clinical and home markets.
Products and commercial strategy: the role of wearable robotics for rehabilitation
Wearable Robotics, a spin-off founded in 2014 by the Scuola Superiore Sant'Anna of Pisa, develops exoskeletons and wearable devices for rehabilitation, movement assistance and augmentation of human capabilities. Our flagship product ALEX RS is a bilateral device for upper limb rehabilitation with more than 50 units installed internationally.
The focus on modular and AR/VR-integrated solutions improves functional recovery in daily activities and enables more effective rehabilitation protocols.
Divisions and practical applications
The company operates with two main divisions: NEXUM Medical, dedicated to neuromotor rehabilitation of the upper limb and integration with VR systems for training; and NEXUM Industry, which develops exoskeletons to facilitate lifting tasks and reduce worker fatigue. This structure allows addressing both the healthcare market and the industrial market with different solutions but sharing the same technological know-how.
Funding, investors and regional impact
The €5 million round was led by CDP Venture Capital through the Accelerators Fund, with participation from MITO Technology (MITO Tech Transfer), LIFTT, SIMEST and other regional players such as Toscana Next and RoboIT. The operation combines institutional capital and local tools to maximize the investment in the Tuscan innovation ecosystem.
Wearable Robotics reports owning a family of eight proprietary patents covering the developed know-how and being present in 20 countries. Intellectual property and the international commercial network are key levers for scalability.
The strengthening of intellectual property and regulatory certifications is essential to access overseas clinical markets and to accelerate adoption by healthcare facilities.
Regulation and time-to-market
Among the company's explicit objectives is to complete the regulatory processes needed to access the reference markets and reduce time-to-market. Investing in regulatory compliance helps unlock hospital contracts and procurement tenders in areas with stringent requirements.
International plan and sales channels
The strategy calls for strengthening sales channels and new partnerships to increase local presence, with particular focus on the North American market. Putting resources into distribution and local partnerships accelerates clinical adoption and commercial penetration.
Critical analysis: opportunities, risks and scenarios for wearable robotics for rehabilitation
The rehabilitation robotics sector offers significant opportunities but also concrete constraints: high development and certification costs, the need for clinical studies demonstrating efficacy relative to existing standards, and the challenge of integrating complex hardware solutions into existing therapeutic pathways. For a founder, balancing investment in R&D, clinical validation, and business development is key to overcoming adoption barriers.
On the positive side, devices like ALEX RS demonstrate there is real demand from clinics, rehabilitation centers and private facilities; added value comes from integration with AR/VR and a modular approach that allows updates and adaptations to different rehabilitation districts. Solutions that improve Activities of Daily Living (ADLs) have a higher likelihood of being adopted by therapists and hospital decision-makers.
However, controlled clinical studies and published data supporting claims of functional efficacy are needed to persuade national health systems and payers to reimburse such devices. The collection of outcome and cost-effectiveness evidence is decisive for long-term commercial sustainability.
From a business-model perspective, there are two approaches: direct hardware sales with integrated services (training, maintenance, software updates) or subscription-and-service models that reduce the initial entry barrier for facilities. Choosing the right model can accelerate adoption and stabilize revenue streams.
Finally, competition in the field of exoskeletons and robotic aids is growing: startups and large industrial players are entering the market with different solutions. Differentiation through patents, software integration and clinical partnerships can serve as a competitive shield.
Practical tips for founders and operators
If you work in a rehabilitation robotics startup, focus on three priorities: clinical validation, regulatory compliance and local sales channels with experienced partners. Planning clinical studies and scheduling certifications from early stages reduces costly go-to-market delays.
Additionally, consider business models that reduce the entry barrier for facilities (operating lease, integrated services), and invest in intellectual property to protect technological advantages. Adopting modular, software-updatable solutions increases perceived value for customers and enables recurring revenue.
Implications for investors
For investors, the segment is attractive but patience is required: payback times can be longer than pure software solutions due to regulatory cycles and clinical validations. Assessing the clinical team, partnerships with research centers and IP coverage is essential before investing.
Prospects and next steps for Wearable Robotics
The company plans to use the capital to broaden its portfolio, complete regulatory procedures and consolidate commercial channels, with a particular focus on North America. This strategy aims to turn the current competitive edge into a stable international commercial presence.
With eight proprietary patents and a presence in 20 countries, Wearable Robotics combines academic know-how and industrial capabilities to compete in regulated and structured markets. Strengthening the commercial team and gaining access to local partners will be decisive for the next growth phase.
Final note for those seeking practical insights
For a founder operating in the medical field, the Wearable Robotics case underscores the importance of integrating technological innovation, IP protection and regulatory strategy from the outset. Investing simultaneously in clinical evidence and differentiated sales channels reduces the risk of bottlenecks during scale-up.
Article based on press releases and public statements provided by the company. Keeping clinical and regulatory sources up to date is essential to assess real progress against commercial promises.
